| Bid | 16.75 |
| Market Cap | 1.11B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 0.81 |
| PE Ratio (ttm) | 21.83 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 18.71 |
| Volume | 606,789 |
| Avg. Volume (20D) | 619,096 |
| Open | 17.50 |
| Previous Close | 17.56 |
| Day's Range | 17.50 - 17.78 |
| 52-Week Range | 14.33 - 21.28 |
| Beta | undefined |
About INVA
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY...
Analyst Forecast
According to 1 analyst ratings, the average rating for INVA stock is "Buy." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.
Next Earnings Release
Analysts project revenue of $86.80M, reflecting a 1.12% YoY growth and earnings per share of 0.37, making a -51.32% decrease YoY.
1 month ago · businesswire.com
Innoviva to Participate in the Citi 2024 Global Healthcare ConferenceBURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...
